Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 190.00
Bid: 185.00
Ask: 195.00
Change: 0.00 (0.00%)
Spread: 10.00 (5.405%)
Open: 190.00
High: 190.00
Low: 190.00
Prev. Close: 190.00
SNX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

1 Mar 2016 16:48

RNS Number : 6932Q
Synectics PLC
01 March 2016
 

 

1 March 2016

 

 

 

Synectics plc

(the "Company" or the "Group")

Award of Options under Share Plan

Directors' shareholdings

 

Synectics (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, announces that earlier today it made awards over 155,000 Synectics plc ordinary shares of 20p (the "Shares") to certain senior managers employed within the Group, under its Performance Share Plan ("PSP").

 

Under the PSP, selected employees are entitled to exercise an option to receive a certain number of Synectics shares at any time after a 3 year vesting period, at no cost to themselves. The number of shares that are awarded at the end of the 3 year period is dependent on the achievement of certain performance criteria.

 

Vesting of the PSP awards is dependent on the total return on Synectics' shares compared with the AIM All Share Total Return Index (the "Index"). If the total return on Synectics' shares out-performs the Index by 5% or more in the 3 years following the award, all of the Shares awarded will vest. If Synectics' shares match the Index performance, then 25% of the awarded Shares will vest. Between these points the number of Shares that vest will be pro-rata. If the total return on Synectics' shares underperforms the Index, then no Shares will vest. The limit on the number of shares over which interests may be awarded remains unchanged.

 

Any entitlement under the PSP will lapse on cessation of employment prior to the end of the 3 year vesting period, unless cessation of employment is by reason of redundancy, ill health or death.

 

Should the performance criteria be met in full or part, it is intended that the appropriate number of Shares will be satisfied from unallocated Synectics' shares already held within the Company's employee benefit trust.

 

Full details of the PSP were set out in the Company's Annual Report for the year ended 30 November 2014.

Under the PSP award, Paul Webb and Mike Stilwell, executive directors of the Company, were awarded 30,000 Shares and 15,000 Shares respectively. Following the awards, their total interests in Synectics' shares are now as follows:

Director

Position

Beneficial Interest

Interest in Share Schemes

ResultantTotalInterest

% ofIssuedShare Capital

Paul Webb

Chief Executive

0

298,883

298,883

1.68%

Mike Stilwell

Finance Director

2,910

48,574

51,484

0.29%

.

 

For further information, please contact:

Synectics plc

Tel: +44 (0) 1527 850080

Richard Brierley, Deputy Company Secretary

www.synecticsplc.com

Stockdale Securities Limited

Tel: +44 (0) 207 601 6100

Tom Griffiths

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAKDFELKKEFF
Date   Source Headline
4th Feb 20097:00 amRNSInterim Results
16th Jan 200912:06 pmRNSNotification of Results
3rd Sep 20087:00 amRNSPreliminary Results
6th Feb 20087:01 amRNSInterim Results
16th Jan 20087:00 amRNSNotification of Results
6th Dec 20071:09 pmRNSCanc of AIM trading facility
6th Dec 20079:56 amRNSOffer Update
30th Nov 20077:01 amRNSOffer Update
29th Nov 20077:01 amRNSOffer Update
26th Nov 200712:34 pmRNSResult of EGM
23rd Nov 20079:57 amRNSRule 8.1- Synexus
19th Nov 20079:40 amRNSRule 8.1- Synexus
16th Nov 200710:00 amRNSRule 8.1- Synexus
15th Nov 20073:00 pmBUSRule 8.3 - Synexus Clinincal Research Plc
15th Nov 200712:07 pmBUSRule 8.3 - Synexus Clinical Research Plc
15th Nov 20079:16 amRNSRule 8.1- Synexus
14th Nov 20073:21 pmBUSRule 8.3 - Synexus Clinical Research Plc
13th Nov 20073:16 pmBUSRule 8.3 - Synexus Clinical Research Plc
7th Nov 20074:38 pmRNSOffer Document Posted
7th Nov 20077:02 amRNSOffer for Synexus
6th Nov 20079:10 amRNSRule 8.3- Synexus
22nd Oct 200710:46 amRNSHolding(s) in Company
19th Oct 20076:21 pmRNSResponse to price movement
28th Sep 20077:02 amRNSPre Close Statement
5th Sep 20078:33 amRNSBoard Change
5th Sep 20077:01 amRNSPreliminary Results
22nd Aug 20073:17 pmRNSHolding(s) in Company
22nd Aug 200711:19 amRNSAIM RULE 26
15th Jun 20071:26 pmRNSGrant of Options
13th Jun 20077:01 amRNSPreliminary Results
24th May 20074:24 pmRNSNotice of Results
8th Mar 20077:00 amRNSHolding(s) in Company
20th Feb 200712:33 pmRNSGrant of Options
7th Feb 20077:02 amRNSNorth American Contract Wins
7th Feb 20077:02 amRNSInterim Results
6th Feb 200710:14 amRNSDirector/PDMR Shareholding
5th Feb 20077:00 amRNSDirectorate Change
29th Jan 20072:58 pmRNSNotice of Results
26th Jan 20077:01 amRNSTrading Update
28th Dec 20064:36 pmRNSGrant of Options
22nd Dec 20069:37 amRNSTotal Voting Rights & Capital
5th Dec 20067:01 amRNSInterim Results
29th Nov 20063:25 pmRNSDirector/PDMR Shareholding
24th Nov 200611:53 amRNSNotice of Results
24th Oct 20067:01 amRNSAcquisition
4th Oct 20067:00 amRNSTrading Statement
18th Sep 20069:11 amRNSDirectorate Change
13th Jul 20067:01 amRNSIssue of Equity
20th Jun 200610:39 amRNSGrant of Options
14th Jun 20065:06 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.